DILIsym Services Presents Important DILIsym and NAFLDsym Software Applications at the Virtual AASLD Liver Meeting
Summary
Quantitative systems pharmacology (QSP) work was presented by Dr. Zack Kenz focused on a NAFLDsym software application for the agonist anti-FGFR1/KLB bispecific antibody, BFKB8488A. Dr. Scott Q. Siler, Chief Scientific Officer of DILIsym Services, said: “Our 2020 virtual Liver Meeting posters on remdesivir and BFKB8488A show our continued commitment to great science and important collaborations, even in the midst of the turbulent year of 2020. Kyunghee and Zack should be commended for their excellent work.” Dr. Brett A. Howell, President of DILIsym Services, added: “These applications in both safety and efficacy are critical examples of our many great partnerships with the pharmaceutical industry. NAFLDsym and IPFsym are designed for target or compound evaluation of therapeutic efficacy in nonalcoholic fatty liver disease (NAFLD or NASH) and idiopathic pulmonary fibrosis (IPF), respectively. In addition to performing consulting services using the modeling software, the expert scientific team engages clients from initial program design through data input and “results” interpretation.
Classifications
AskAI Classifications
LabelsLinked Companies
